Current FDA Status
- Phase 3 obesity trials fully enrolled: SYNCHRONIZE-1 (726 patients) and SYNCHRONIZE-2 (755 patients) completed enrollment[1]
- Phase 3 MASH trials initiated: LIVERAGE program (~3,390 patients) launched October 2024[2]
- FDA Breakthrough Therapy: Granted for MASH (September 2024)[2]
- FDA Fast Track: Granted for NASH[3]
- EMA PRIME: Granted for MASH with fibrosis (November 2023)
- Phase 3 results expected: H1 2026
- FDA approval projected: 2027 (for obesity indication)
Safety established
18.7% weight loss
SYNCHRONIZE
Application to FDA
Expected approval
Regulatory Designations
Survodutide has received multiple regulatory designations that could expedite review and approval:
| Designation | Agency | Indication | Date |
|---|---|---|---|
| Breakthrough Therapy | FDA (US) | Non-cirrhotic MASH | Sept 2024 |
| Fast Track | FDA (US) | NASH | Previously granted |
| PRIME | EMA (EU) | MASH with fibrosis | Nov 2023 |
| Breakthrough Therapy | NMPA (China) | MASH | June 2024 |
What These Designations Mean
Breakthrough Therapy designation provides intensive FDA guidance, rolling review eligibility, and organizational commitment. Fast Track allows rolling review and more frequent FDA meetings. These designations significantly increase the likelihood of timely approval—though they don't guarantee it.
Note: Current designations are primarily for MASH, not obesity. Obesity approval will follow the standard pathway unless additional designations are granted.
Phase 3 Program Details
SYNCHRONIZE Program (Obesity)[1]
- SYNCHRONIZE-1: 726 adults with obesity without T2D, 76 weeks, enrollment completed Nov 2023
- SYNCHRONIZE-2: 755 adults with obesity + T2D, 76 weeks, enrollment completed June 2024
- SYNCHRONIZE-CVOT: Long-term cardiovascular outcomes trial, ongoing
- Doses: Survodutide 3.6mg or 6.0mg weekly vs. placebo
- Primary endpoints: Weight change and ≥5% responders at week 76
- Results expected: H1 2026
LIVERAGE Program (MASH)[2]
- LIVERAGE: ~1,800 adults with MASH + fibrosis F2/F3
- LIVERAGE-Cirrhosis: ~1,590 adults with MASH + compensated cirrhosis F4
- Status: Initiated October 2024, currently enrolling
- Results expected: 2027-2028 (estimated)
Development Timeline
| Milestone | Status | Timeframe |
|---|---|---|
| Phase 2 Obesity (Lancet) | ✓ Complete | 2023 |
| Phase 2 MASH (NEJM) | ✓ Complete | 2024 |
| SYNCHRONIZE enrollment | ✓ Complete | Nov 2023-June 2024 |
| FDA Breakthrough (MASH) | ✓ Granted | Sept 2024 |
| LIVERAGE initiation | ✓ Started | Oct 2024 |
| SYNCHRONIZE results | ⟳ Pending | H1 2026 |
| NDA submission (obesity) | ⧗ Projected | Late 2026 |
| FDA approval (obesity) | ⊕ Projected | 2027 |
Approval Predictions
Best-Case Scenario
Timeline: Late 2026 / Early 2027 approval
What would need to happen:
- SYNCHRONIZE results by Q1 2026
- Immediate NDA filing with compelling data
- Priority Review granted (6 months)
- No FDA questions or manufacturing issues
Most Likely Scenario
Timeline: Mid-to-late 2027 approval
Assumptions:
- SYNCHRONIZE results H1 2026
- NDA filing late 2026
- Standard review (10-12 months)
- Approval H2 2027
Delayed Scenario
Timeline: 2028 or later
Potential causes:
- Phase 3 safety signals requiring additional data
- Efficacy doesn't match Phase 2 expectations
- FDA requests cardiovascular outcomes data
- Manufacturing scale-up delays
Summary: Survodutide is on track for FDA approval in 2027. Boehringer Ingelheim is a large pharmaceutical company with strong regulatory experience. The key catalyst is SYNCHRONIZE Phase 3 results in H1 2026—positive data would confirm the approval trajectory.
FAQs
FDA approval for the obesity indication is projected for 2027. The SYNCHRONIZE Phase 3 trials (76 weeks) with enrollment completed means results are expected in H1 2026. NDA filing and FDA review would follow, targeting approval in 2027.
MASH approval may follow a slightly different timeline depending on LIVERAGE trial results.
No. Survodutide is not yet FDA-approved and is only available through clinical trial participation. Check ClinicalTrials.gov for:
- SYNCHRONIZE-CVOT: May have sites still enrolling
- LIVERAGE: MASH trials may be actively enrolling
Survodutide is in the middle of the pack for next-generation obesity drugs:
- Zepbound/Wegovy: Already FDA-approved
- CagriSema: NDA filing expected Q1 2026, approval late 2026/2027
- Orforglipron (oral): Phase 3 results 2025, approval 2026-2027
- Survodutide: Phase 3 results H1 2026, approval 2027
- Retatrutide: Phase 3 ongoing, approval 2027-2028
MASH approval is a high priority. Survodutide has FDA Breakthrough Therapy designation for MASH, and Phase 2 showed up to 62% MASH resolution vs. 14% placebo (NEJM 2024). The LIVERAGE Phase 3 trials initiated in October 2024 will support the MASH NDA.
MASH approval may come slightly after or around the same time as obesity approval, depending on trial completion timing.
Sources & References
- Wharton S, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity. 2025;33(1):44-54. https://pubmed.ncbi.nlm.nih.gov/39495965/
- Boehringer Ingelheim. Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity. August 2023. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/survodutide-phase-iii-study-weight-loss
- Zealand Pharma. Survodutide Pipeline. https://www.zealandpharma.com/pipeline/survodutide/
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391:311-319. https://pubmed.ncbi.nlm.nih.gov/38847460/
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.